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New York, New York; Quebec City, Quebec, and Vancouver, British Columbia, Canada;
Philadelphia, Pennsylvania; Los Angeles and Irvine, California; Kansas City, Missouri;
Atlanta, Georgia; and Cleveland, OhioObjectives This study sought to characterize the patients receiving post-implantation balloon dilation
(PD) following transcatheter aortic valve replacement (TAVR) and evaluate procedural outcomes in
the PARTNER (Placement of Aortic Transcatheter Valve) I trial.
Background Following TAVR, PD has been used to treat paravalvular regurgitation.
Methods The PARTNER I trial cohort A (n ¼ 304) and cohort B (n ¼ 194) patients randomized to TAVR
and the nonrandomized continued access TAVR (n ¼ 1,637) patients were included in the analysis. PD
was performed at the discretion of the operator. Clinical events and echocardiographic variables were
collected prospectively out to 1 year.
Results The overall incidence of PD was 12.4%. PD patients had signiﬁcantly less prosthesis-patient
mismatch (p < 0.001) and larger effective oriﬁce areas (p < 0.001) throughout the follow-up
period. There were signiﬁcantly more subacute strokes (occurring <7 days: 4.9% vs. 2.6%; p ¼ 0.04)
in PD patients but no difference in late stroke, either at 7 to 30 days (0.0% vs. 0.8%; p ¼ 0.16)
or >30 days (1.9 vs. 1.7%; p ¼ 0.75). Although there was no signiﬁcant increase in early mortality
with PD, at 1 year, there was a trend for higher all-cause mortality (p ¼ 0.054) and a signiﬁcant
difference in death or stroke (p ¼ 0.04). When the subgroup of patients with none/trace paravalvular
regurgitation were evaluated, there was no signiﬁcant association of PD with mortality (p ¼ 0.61)
and death or stroke (p ¼ 0.96). Multivariable analysis failed to show a relationship between PD
and mortality.
Conclusions PD is associated with reduced rates of moderate or severe prosthesis-patient mismatch
with no evidence for short-term structural deterioration of the balloon-expandable transcatheter valve.
Although PD is associated with a greater incidence of early stroke, there is no signiﬁcant association
between PD and stroke beyond 7 days. Multivariable analysis shows no signiﬁcant association between
PD and mortality. (J Am Coll Cardiol Intv 2014;7:781–9)ª 2014 by the American College of Cardiology
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782Transcatheter aortic valve replacement (TAVR) has
emerged as an alternative to surgical aortic valve replace-
ment for patients with severe aortic stenosis who are at
“high risk” or deemed inoperable (1,2) despite a higher
incidence of post-TAVR paravalvular regurgitation (PVR)
(3). Numerous studies have shown an association between
post-procedural PVR and increased late mortality (4–9),
generating intense interest in determining predictors or
treatment of this complication. Reballooning or post-
implantation balloon dilation (PD) of balloon expandable
valves after implantation has been proposed as an effective
method to reduce post-TAVR PVR (10–13). Potential risks
of PD include transcatheter heart valve migration or injury,
trauma to the conduction system, rupture of the membra-
nous septum or aorta, and cerebrovascular embolismLifesciences, Irvine, California; and t
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Abbreviations
and Acronyms
CABG = coronary artery
bypass graft
CI = conﬁdence interval
EOA = effective oriﬁce area
HR = hazard ratio
LV = left ventricular
NoPD = no post-dilation
PD = post-dilation
PPM = prosthesis-patient
mismatch
PVR = paravalvular
regurgitation
TAVR = transcatheter aortic
valve replacement(11,12,14). Further understand-
ing of the risk of PD would have
important consequences to pro-
cedural technique and the perfor-
mance of a potentially life-saving
treatment. We thus sought to
determine the baseline predictors
of PD and the effect of PD on
valve hemodynamics and out-
comes in the PARTNER I trial.
Methods
Study design and patient popu-
lation. Randomized patients
from cohort B (inoperable) and
cohort A (high-risk) patients of
the PARTNER trial with severe,symptomatic aortic stenosis receiving a TAVR with the
Edwards Sapien valve (Edwards Lifesciences, Irvine, Cali-
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e Medical; has received consulting fees frompatients, were studied. Inclusion criteria for this trial
included a site-measured echocardiographic aortic valve area
of <0.8 cm2 plus either a peak aortic jet velocity 4 m/s or a
mean gradient 40 mm Hg at rest or during dobutamine
infusion. The design, inclusion, and exclusion criteria and
primary results of the PARTNER trial have been reported
(1,2). Echocardiograms were obtained at baseline, 7 days, 30
days, 6 months, 1 year, and 2 years post-procedure. For this
post-hoc analysis, randomized control trial patients from
cohort A (n ¼ 304) and cohort B (n ¼ 194), as well as
nonrandomized continued access TAVR (n ¼ 1,637) pa-
tients, were evaluated.
Procedural method. TAVR was performed as previously
described (1). PD was performed at the discretion of the
operator, in most cases where PVR was deemed qualitatively
more than mild by hemodynamic measurements, ﬂuoro-
scopic assessment, and/or transesophageal echocardiography
immediately after transcatheter heart valve implantation.
PD was performed with the same implantation balloon
under rapid-pacing runs similar to initial valve deployment.
PD was performed using either the same volume or with an
additional 0.5 to 2 cc in the inﬂation syringe as determined
by the operator. The balloon was typically positioned slightly
more toward the apex for PD. A repeat PD could be per-
formed at the discretion of the operator.
Doppler-echocardiographic measurements. All baseline and
follow-up echocardiograms were interpreted by an inde-
pendent core laboratory housed at the Duke Clinical
Research Institute. Study workﬂow, reproducibility testing,
image acquisition and analysis, and quality assurance data
have been published (15). Ventricular size and function and
valvular function were measured according to previously
published guidelines (16). The stroke volume was measured
in the left ventricular (LV) outﬂow tract with the use of the
diameter and velocity measured just underneath the pros-
thesis stent (17). The effective oriﬁce area (EOA) was
calculated as the LV outﬂow tract stroke volume divided by
the aortic jet velocity time integral and was indexed for body
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Table 1. Baseline Clinical Characteristics
PD NoPD p Value
Age, yrs 84.30  6.98 (264) 84.43  7.27 (1,869) 0.64
Male 72.7 (192/264) 49.8 (931/1,869) <0.0001
BSA, m2 1.88  0.29 (264) 1.79  0.25 (1,863) <0.0001
BMI, kg/m2 26.17  6.34 (264) 26.74  6.41 (1,863) 0.23
STS score 11.49  3.55 (263) 11.53  4.26 (1,867) 0.7
Logistic EuroSCORE 27.28  16.34 (245) 26.83  16.25 (1,821) 0.6
Diabetes 34.8 (92/264) 38.3 (716/1,869) 0.28
Hyperlipidemia 83.7 (221/264) 83.7 (1,565/1,869) 0.99
Smoking 61.0 (161/264) 45.8 (856/1,869) <0.0001
Hypertension 91.3 (241/264) 92.1 (1,721/1,868) 0.64
Cerebrovascular disease 24.6 (61/248) 27.1 (499/1,841) 0.4
Peripheral vascular disease 39.9 (105/263) 43.7 (807/1,848) 0.25
Porcelain aorta 2.3 (6/264) 3.9 (72/1,866) 0.2
CHF 97.7 (257/263) 98.3 (1,836/1,868) 0.46
NYHA functional class I 0.0 (0/264) 0.1 (2/1869)
NYHA functional class II 4.9 (13/264) 4.6 (86/1,869)
NYHA functional class III 54.9 (145/264) 46.3 (865/1,869)
NYHA functional class IV 40.2 (106/264) 49.0 (916/1,869)
Angina 20.1 (53/264) 21.5 (401/1,869) 0.61
CAD 82.6 (218/264) 77.1 (1,441/1,868) 0.05
Previous CABG 53.4 (141/264) 41.4 (773/1,868) 0.002
Pulmonary hypertension 45.0 (113/251) 38.0 (674/1,775) 0.03
Major arrhythmia 57.2 (151/264) 49.5 (924/1,868) 0.02
Values are mean  SD (n) or % (n/n).
BMI ¼ body mass index; BSA ¼ body surface area; CABG ¼ coronary artery bypass graft;
CAD ¼ coronary artery disease; CHF ¼ congestive heart failure; EuroSCORE ¼ European System
for Cardiac Operative Risk Evaluation; NoPD ¼ not receiving post-dilation; NYHA ¼ New York
Heart Association functional class; PD ¼ post-dilation; STS ¼ Society of Thoracic Surgeons.
Table 2. Baseline Echocardiographic Characteristics
PD NoPD p Value
LVED, cm 4.67  0.75 (232) 4.48  0.75 (1,685) 0.0007
LV mass, g 270.15  77.29 (232) 247.32  76.57 (1,683) <0.0001
LV EF, biplane Simpson
method, %
50.42  13.06 (258) 52.96  12.86 (1,830) 0.003
Stroke volume, ml 68.56  19.32 (121) 65.57  21.19 (882) 0.09
Cardiac output, l/min 4.65  1.46 (121) 4.45  1.48 (880) 0.12
Aortic annulus, cm 1.98  0.28 (197) 1.90  0.27 (1,445) <0.0001
STJ, cm 2.50  0.37 (168) 2.34  0.38 (1,252) <0.0001
Mean gradient, mm Hg 44.6  13.0 (256) 44.1  14.4 (1,813) 0.44
EOA, cm2 0.66  0.19 (249) 0.65  0.19 (1,790) 0.42
EOAi, cm2/m2 0.35  0.10 (249) 0.37  0.11 (1,782) 0.14
Values are mean  SD (n).
EF ¼ ejection fraction; EOA ¼ effective oriﬁce area; EOAi ¼ effective oriﬁce area indexed for
body surface area; LV ¼ left ventricle; LVED ¼ left ventricular end-diastolic dimension;
STJ ¼ sino-tubular junction; other abbreviations as in Table 1.
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783as the ratio of the LV outﬂow tract and transaortic velocity-
time integrals. An integrative, semiquantitative approach
was used to assess the severity of native valve regurgitation
(19) and PVR (20). The severity of prosthesis-patient
mismatch (PPM) was graded using indexed EOA as pre-
viously described (20) with the absence of PPM deﬁned as
an indexed EOA >0.85 cm2/m2, moderate PPM deﬁned
as an indexed EOA between 0.65 and 0.85 cm2/m2, and
severe PPM as an indexed EOA <0.65 cm2/m2. The cover
index was calculated as the percentage of difference between
the nominal transcatheter heart valve diameter and the
site-reported systolic annular diameter, divided by the
nominal transcatheter heart valve diameter (21).
Clinical endpoints. The primary and secondary endpoints
for the PARTNER trial have been previously described
(1,2). Of note, major stroke was deﬁned by a score of 2 on
the modiﬁed Rankin scale performed at the time of the event
(which ranges from 0 to 6, with higher scores indicating
greater disability) in a retrospective analysis of neurologic
events adjudicated by the clinical events committee. Timing
of strokes was also determined and deﬁned as: acute <24 h,
subacute >24 h but <7 days, and late >7 days.
Statistical analysis. The study population was the actual
valve implant population who received and retained the
transcatheter heart valve. Because of the difﬁculty in imaging
patients immediately following intervention, the ﬁrst post-
implantation values are those obtained from the ﬁrst evalu-
able echocardiogram obtained at either discharge or 7 days.
Categorical variables were compared using Fisher exact
test. Both regurgitation and New York Heart Association
functional class are ordinal variables and comparisons
involving these variables use the Mann-Whitney U test.
Continuous variables were presented as means  SD and
compared using Student t test or analysis of variance. A 2-
way analysis of variance with repeated measures in one factor
(mixed-model analysis of variance) was used to compare
between group differences over time. Survival curves for
time-to-event variables were constructed using Kaplan-
Meier estimates based on all available data and were
compared using the log-rank test. To study the impact of
risk factors on mortality, Cox proportional hazards regres-
sion was performed.
Multivariable analysis was performed for 1-year mortality
using the baseline variables that differed between PD groups
(p  0.10) with PD as a forced variable.
Data are based on an extract date of February 14, 2013.
All statistical analyses were performed in SAS (version 9.2,
SAS Institute, Cary, North Carolina).
Results
Baseline clinical, procedural, and echocardiographic
characteristics. The overall incidence of PD was 12% (261
of 2,123) in the pooled cohort, 15% in cohort A (46 of259), 7.6% in cohort B (12 of 145), and 12.4% in non-
randomized continued access patients (207 of 1,469). PD
patients were more likely to be male (p < 0.0001); have
larger body surface area (p < 0.0001); and to have a history
Table 4. Post-TAVR Echocardiographic Variables
PD NoPD p Value
Discharge
LVED, cm 4.68  0.77 (233) 4.48  0.78 (1,667) 0.0001
LV mass, g 268.13  79.03 (232) 240.65  74.96 (1,665) <0.0001
LV EF, % 52.50  11.64 (263) 54.41  11.67 (1,865) 0.004
Stroke volume, ml 74.13  25.02 (87) 67.29  22.04 (628) 0.01
Cardiac output, l/min 5.23  1.82 (394) 4.89  1.48 (410) 0.004
Mean gradient, mm Hg 9.56  4.04 (258) 10.79  4.77 (1,806) <0.0001
EOA, cm2 1.82  0.53 (247) 1.61  0.47 (1,749) <0.0001
EOAi, cm2/m2 0.96  0.30 (230) 0.91  0.28 (1,553) 0.003
30 days
LVED, cm 4.74  0.76 (225) 4.50  0.77 (1,540) <0.0001
LV mass, g 255.75  76.78 (223) 230.43  73.91 (1,539) <0.0001
LV EF, %* 52.41  10.63 (239) 54.72  11.15 (1,670) 0.0007
Stroke volume, mly 77.78  23.31 (100) 68.89  21.73 (646) 0.0003
Cardiac output, l/min 5.21  1.63 (100) 4.74  1.62 (644) 0.004
Mean gradient, mm Hg 8.44  3.36 (234) 9.31  3.84 (1,645) 0.0006
EOA, cm2 1.85  0.51 (232) 1.69  0.49 (1,606) <0.0001
EOAi, cm2/m2 1.00  0.29 (219) 0.96  0.28 (1,543) 0.01
1 year
LVED, cm 4.65  0.85 (86) 4.43  0.79 (650) 0.01
LV mass, g 256.87  92.45 (86) 219.23  74.83 (650) 0.0002
LV EF, % 56.73  9.99 (92) 55.86  9.84 (728) 0.28
Stroke volume, ml 82.82  23.68 (44) 66.71  21.58 (271) <0.0001
Cardiac output, l/min 5.40  1.66 (44) 4.39  1.46 (270) <0.0001
Mean gradient, mm Hg 9.79  4.99 (92) 10.11  4.05 (718) 0.13
EOA, cm2 1.78  0.48 (90) 1.60  0.44 (692) 0.0002
EOAi, cm2/m2 0.96  0.27 (87) 0.90  0.27 (676) 0.02
Values are mean  SD (n). *Calculated by biplane Simpson method. yCalculated by
Doppler method.
Abbreviations as in Tables 1 to 3.
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784of smoking (p < 0.0001), coronary artery disease (p ¼ 0.05),
coronary bypass surgery (p ¼ 0.002) (Table 1), pulmonary
hypertension (p ¼ 0.03), and major arrhythmias (p ¼ 0.02).
There were no between-group differences in Society of
Thoracic Surgeons score or Logistic EuroSCORE (Euro-
pean System for Cardiac Operative Risk Evaluation), or
other cardiovascular risk factors.
On echocardiography (Table 2), there was no signiﬁcant
difference in baseline mean gradient (p ¼ 0.44) or indexed
EOA (p ¼ 0.14); however, PD patients had larger LV
dimensions and volumes (p < 0.01), greater LV mass
(p < 0.0001), worse LV function (p < 0.01), larger annular
diameters (p < 0.0001), and larger aortic root diameters
(p < 0.0001).
Procedural differences between PD and no post-dilation
(NoPD) patients were also seen (Table 3). PD patients were
more like to receive a 26-mm valve (p < 0.0001) and had
signiﬁcantly longer total procedural time (p < 0.001), time
in the catheterization laboratory (p < 0.01), and ﬂuoroscopy
time (p < 0.001). The cover index for PD patients was
signiﬁcantly smaller (10.93  5.47% vs. 12.42  5.47%,
p < 0.001). The PD rates were not signiﬁcantly different in
the transfemoral versus transapical access patients (13.4% vs.
10.9%, p ¼ 0.10).
Echocardiographic outcomes. Echocardiographic variables
following TAVR are listed in Table 4. Ventricular volumes
and mass continued to be larger in the PD patients at 2 years
follow-up. Ejection fraction was lower in the PD patients at
baseline (Table 2), as well as immediately following TAVR
(52.5  11.6% vs. 54.4  11.7%, p ¼ 0.004); however,
ejection fraction was not signiﬁcantly different at 1 yearTable 3. Procedural and Post-Procedural Characteristics
PD NoPD p Value
Valve size <0.0001
23 mm 38.4 (99/258) 54.2 (1,004/1,852)
26 mm 61.6 (159/258) 45.7 (847/1,852)
Cover index, % 10.93  5.47 (258) 12.42  5.47 (1,850) <0.0001
Time in cath lab, min 235.36  101.59 (264) 228.80  70.43 (1,867) 0.004
Total procedure
time, min
132.32  71.97 (262) 119.82  62.46 (1,866) 0.0003
Fluoroscopy time, min 22.55  13.82 (253) 20.39  14.88 (1,781) 0.0009
Days in hospital 44.75  53.78 (159) 45.18  58.02 (1,195) 0.49
Days in hospital
post-TAVR
6.47  2.88 (159) 6.43  11.03 (1,195) 0.27
Procedure success 78.4 (207/264) 81.2 (1,520/1,871) 0.27
NIH stroke score at
discharge
0.24  0.87 (262) 0.26  0.83 (1,860) 0.65
Baseline 6-min walk, m 147.10  103.66 (189) 167.52  107.16 (1,145) 0.01
30-day 6-min walk, m 181.26  97.32 (170) 193.86  112.73 (1,145) 0.28
Values are % (n/n) or mean  SD (n).
cath lab¼ catheterization laboratory; NIH¼National Institutes of Health; TAVR¼ transcatheter
aortic valve replacement; other abbreviations as in Table 1.(56.7  10.0% vs. 55.9  9.8%, p ¼ 0.28) and 2 years (56.0
 9.28% vs 55.8  9.7%, p ¼ 0.90) following the
procedure. The PD group had larger EOA and indexed
EOA than did the NoPD group (p < 0.001) (Fig. 1). PVR
at discharge or 7 days was greater in the PD group (p <
0.0001): none/trace, 38.7% versus 54.9%; mild, 49.2%
versus 36.8%; moderate/severe, 12.1% versus 8.2% (Fig. 2).
Patients who underwent PD had signiﬁcantly (p < 0.001)
less PPM at 30 days (overall: 31%; moderate: 22%; severe:
9%) than did patients with NoPD (overall: 46%; moderate:
32%; severe: 14%). A multivariable analysis was performed
to determine whether PD was independently associated with
less PPM using the covariates of sex, body surface area,
annulus diameter, prosthesis size, cover index, baseline
EOA, and PD. In this analysis, PD remained a predictor of
less PPM (p ¼ 0.002). A smaller EOA, larger body surface
area, and use of the 23-mm valve were predictive of severe
PPM (p < 0.001). Over time, there was no signiﬁcant
change in mean gradients (p ¼ 0.21 for PD and p ¼ 0.74
for NoPD) or EOA (p ¼ 0.35 for PD and p ¼ 0.58
for NoPD).
Figure 1. Echocardiographic Hemodynamics
The mean gradient and aortic valve area in the post-dilation (PD) and no post-
dilation (NoPD) groups are shown from baseline to 1 year. Over time, there is
no signiﬁcant within group differences in mean gradient or aortic valve area
from discharge to 1 year. AV ¼ aortic valve; EOA ¼ effective oriﬁce area.
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785Clinical outcomes. In-hospital, 30-day, and 1-year clinical
outcomes are listed in Table 5. There was no difference
between PD and NoPD patients in all-cause mortality,
cardiovascular mortality, or mortality þ repeat hospitaliza-
tion in the immediate post-procedure (30-day) time frame.
There was a trend toward increased in-hospital stroke in the
PD patients (4.9% vs. 2.9%, p ¼ 0.08); however, no sig-
niﬁcant difference was seen at 30 days (4.9% vs. 3.4%,
p ¼ 0.19) or at 12 months (6.8% vs. 5.0%, p ¼ 0.20)
(Fig. 3A). There is a trend (25.4% vs. 20.3%, p ¼ 0.054)
toward increased all-cause mortality at 1 year in the PD
group (Table 5, Fig. 3B), with a signiﬁcant increase in death
or stroke by 1 year (28.2% vs. 23.0%, p ¼ 0.04) (Fig. 3C).
When only patients with none/trace PVR were evaluated,
however, there was no signiﬁcant difference in death, or
death or stroke (Figs. 4A and 4B).
Multivariable analysis was performed for 1-year mortality
using the baseline variables of sex, body surface area, smoking,
New York Heart Association functional class, coronary artery
disease, coronary artery bypass graft (CABG), pulmonary
hypertension, major arrhythmia (atrial ﬁbrillation), LV end-
diastolic volume, LV end-systolic volume, LV ejection frac-
tion, LV mass, annulus diameter, PD, and post-TAVR PVR
(Table 6). Major arrhythmia (hazard ratio [HR]: 1.58 [95%
conﬁdence interval (CI): 1.26 to 1.98], p ¼ 0.0001), baseline
annular diameter (HR: 2.03 [95% CI: 1.37 to 3.01],
p ¼ 0.0004), and PVR (moderate-severe regurgitation HR:
2.36 [95% CI: 1.72 to 3.24], p < 0.0001) were signiﬁcant
predictors of 1-year mortality. PD was not a signiﬁcant
predictor of mortality.
A similar multivariable analysis was performed for 1-year
mortality or stroke (Table 7). Baseline annular diameter(HR: 1.85 [95% CI: 1.32 to 2.59], p ¼ 0.0003) and PVR
(moderate-severe regurgitation HR: 2.35 [95% CI: 1.75 to
3.17], p < 0.0001) were signiﬁcant predictors of mortality
or stroke. Absence of previous CABG was associated with
a lower risk of mortality or stroke in both models. PD was
not a signiﬁcant predictor of mortality or stroke in either
model.
Kaplan-Meier estimates of 1-year stroke rate (major and
minor strokes) analyzed by timing of the stroke and stratiﬁed
by PD showed no signiﬁcant difference between groups
for acute stroke (HR: 1.71 [95% CI: 0.75 to 3.91],
p ¼ 0.19), but there was an increased risk of subacute stroke
in the PD group (HR: 1.90 [95% CI: 1.03 to 3.49],
p ¼ 0.04). There was no increased risk of late stroke,
either between 7 and 30 days (p ¼ 0.16) or >30 days
(p ¼ 0.75). A multivariable analysis was performed for
acute/subacute stroke (<7 days) using covariates of baseline
annular diameter, prior CABG, approach (transfemoral
vs. transapical), major arrhythmia, baseline-indexed EOA,
and PD (Table 8). Only PD was a signiﬁcant predictor of
acute/subacute stroke (HR: 1.90 [95% CI: 1.03 to 3.50],
p ¼ 0.041).
Discussion
The main ﬁndings of this study are as follows: 1) PD
patients had signiﬁcantly more baseline comorbidities with
larger ventricular and annular dimensions, and worse ven-
tricular function; 2) PD patients did not have a signiﬁcantly
higher risk of stroke at 30 days or 1 year, although there was
a higher incidence of acute/subacute (<7 days) neurologic
events; and 3) when adjusted for residual PVR, PD did not
affect short-term mortality.
Given the association between post-procedural PVR and
increased late mortality (7), determining ways of treating this
procedural complication may have a signiﬁcant impact on
outcomes. A recent meta-analysis (9) identiﬁed 3 primary
predictors of PVR: valve position; Agatston calcium score;
and valve undersizing. In the current study, PD patients had
larger aortic annular and aortic root dimensions and were
more likely to receive a 26-mm transcatheter valve than were
NoPD patients. Because only 2 valve sizes were available (23
mm and 26 mm), patients in the higher annular size range
may have been signiﬁcantly undersized. This is supported by
the lower cover index seen in the PD patients. In this study,
sizing was initially performed using a single sagittal
dimension on echocardiography, with 3-dimensional mea-
surements adopted late in the study. Three-dimensional
sizing algorithms for the annulus are now accepted as the
more accurate measure of annular size. Whether by multi-
slice computed tomography (22–25) or 3-dimensional
transesophageal echocardiography (26–30), the increased
accuracy of either technique (31) is likely to reduce sizing
inaccuracies and may possibly reduce the rate of PD.
Figure 2. PVR at Discharge or 7 Days (Valve Implant Patients)
The incidence of paravalvular regurgitation (PVR) is shown in patients
receiving post-dilation (PD) and those not receiving PD (NoPD) following
transcatheter valve replacement (TAVR).
Table 5. Post-TAVR Outcomes
PD NoPD p Value
In-hospital
Death from any cause 3.0 (8/264) 2.5 (47/1,871) 0.62
Death from cardiovascular cause 1.5 (4/264) 1.3 (24/1,871) 0.77
Stroke 4.9 (13/264) 2.9 (54/1,871) 0.08
Death or stroke 5.7 (15/264) 4.4 (83/1,871) 0.37
30-day adjudicated events (combined in and out of hospital)
Death from any cause 3.4 (9) 3.3 (61) 0.89
Death from cardiovascular cause 2.3 (6) 1.9 (36) 0.7
Death from any cause or
repeat hospitalization
9.5 (25) 9.8 (183) 0.88
Stroke 4.9 (13) 3.4 (63) 0.19
Death or stroke 5.7 (15) 5.5 (102) 0.85
6-month adjudicated events (combined in and out of hospital)
Death from any cause 9.3 (23) 7.7 (139) 0.39
Death from cardiovascular
cause
17.1 (42) 14.8 (263) 0.34
Death from any cause or
repeat hospitalization
28.6 (74) 24.2 (451) 0.13
Stroke 6.3 (16) 4.3 (79) 0.16
Death or stroke 20.9 (54) 16.0 (297) 0.05
1-year adjudicated events (combined in and out of hospital)
Death from any cause 25.4 (63) 20.3 (366) 0.054
Death from cardiovascular
cause
16.9 (39) 12.3 (210) 0.051
Death from any cause or
repeat hospitalization
37.0 (93) 32.9 (596) 0.14
Stroke 6.8 (17) 5.0 (89) 0.2
Death or stroke 28.2 (71) 23.0 (415) 0.04
Values are % (n/n) or % (n).
Abbreviations as in Tables 1 and 3.
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786PD may result in improved hemodynamics following
TAVR. Compared with NoPD, PD patients in this study
had larger EOA and less PPM, which was conﬁrmed on
multivariable analysis. In addition, there was no deteriora-
tion in the acute hemodynamic changes over the study
period. Although PD after TAVR has been proposed as an
effective method to reduce PVR (10–13,32–34), there was
greater residual PVR in the PD versus the NoPD cohort.
Whether this represents an improvement in what would
have been worse PVR post-TAVR, or a poor response to
PD, cannot be determined in this study. Valve calcium
burden has been shown to be a predictor of the need for, as
well as a poor response to, PD (12). Although a calcium
score is not available in this study, patients who received PD
had baseline clinical characteristics such as smoking, coro-
nary artery disease, and previous CABG that may increase
the likelihood of valvular calciﬁcation and thus PVR.
Determining which patients may beneﬁt from PD may help
reduce the performance of ineffective reballooning as well as
increase the safety of the procedure.
The relationship between PD and acute neurologic events
deserves special attention. Early transcranial Doppler studies
have suggested that cerebral embolic events may be more
frequent during prosthesis positioning and implantation
(35,36). Nombela-Franco et al. (14) showed that PD was
a predictor of early (24 h) cerebrovascular events (14).
In their multicenter study of the predictors of cerebrovas-
cular events, timing of the events was meticulouslydocumented (either prospectively or retrospectively). Pre-
dictors of acute (24 h) events were PD and valve embo-
lization/dislodgement, whereas predictors of subacute
(occurring 1 to 30 days after TAVR) events were PD and
new onset atrial ﬁbrillation. In the current study, the in-
hospital trend of greater neurologic events in the PD group
was driven by a signiﬁcantly higher incidence of <7-day
stroke. Although our study failed to show a signiﬁcant
association at the acute stroke, this may be explained in part
by the criteria used to differentiate stroke (signs/symptoms
lasting >24 h) from transient ischemic attack (signs/
symptoms lasting 24 h), as well as post-general anesthesia
management protocols that may prevent accurate early
neurologic assessment. The signiﬁcant association with
<7-day events and PD found in the present study was
conﬁrmed by multivariable analysis, but importantly, there
is no increased risk for stroke with PD after 7 days and up
to 1 year.
Although there was no increased risk of procedural
(30-day) or short-term mortality, our study, unlike previ-
ous studies (12), showed a trend toward increased 1-year
mortality with PD. However, further analysis of patients
Figure 3. Outcomes in the As-Treated Cohort
Kaplan-Meier curves compare outcomes of patients with post-dilation (PD)
and those not receiving post-dilation (NoPD) over 12 months with respect
to stroke (A), death (B), and death or stroke (C). CI ¼ conﬁdence interval;
HR ¼ hazard ratio.
Figure 4. Outcomes in Patients with None/Trace PVR
Kaplan-Meier curves compare outcomes of patients with post-dilation (PD) and
those not receiving post-dilation (NoPD) over 12 months with respect to death
(A), and death or stroke (B) in patients. Abbreviations as in Figures 2 and 3.
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787with none/trace PVR showed no difference in mortality.
In addition, multivariable analysis revealed a signiﬁcant
relationship between PVR and death but no association be-
tween PD and death, strongly supporting the theory that
residual PVR, and not PD, is the determinant of mortality.
Given the association of PVR with increased mortality,
the small increase in <7-day stroke risk with PD maynonetheless be worth the beneﬁt of reducing PVR and
PPM. The indications for PD, however, remain uncertain
because previous reports from the PARTNER trial with
echocardiographic core lab–assessed aortic regurgitation
suggest that even mild PVR is associated with increased
mortality (7), whereas recent large registries suggest increased
mortality is only associated with more-than-moderate PVR
(37,38). These differences are more likely related to the
differences in regurgitation grading schemes rather than
to differences in the mortality rates between grades. It is,
however, abundantly clear that moderate or severe PVR
is associated with increased mortality, and the clinical
practice of performing PD when it is likely to reduce PVR
to less than mild or mild is supported by this study. A
better understanding of which patients will respond to PD
and which patients are at high risk for complications such
Table 8. Multivariable Cox Regression Model for Acute Stroke
HR (95% CI) p Value
Baseline annulus diameter 0.11 (0.01–1.42) 0.0901
Post-dilation 1.90 (1.03–3.50) 0.0409
Acute stroke is deﬁned as stroke occurring within 7 days of implantation. Model:
Potential covariates included baseline annulus diameter, previous CABG, approach (trans-
femoral vs. transapical), major arrhythmia, baseline AV area index. The forced in covariate was
post-dilation.
AV ¼ aortic valve; other abbreviations as in Tables 1 and 6.
Table 6. Multivariable Cox Regression Model for 1-Year Mortality
HR (95% CI) p Value
Major arrhythmia 1.58 (1.26–1.98) <0.0001
Baseline annulus diameter 2.03 (1.37–3.01) 0.0004
Previous CABG 0.81 (0.65–1.01) 0.0622
Paravalvular aortic regurgitation
None/trace 1.16 (0.95–1.43) 0.1411
Mild 1.29 (1.02–1.65) 0.0365
Moderate/severe 2.36 (1.72–3.24) <0.0001
Post-dilation 1.13 (0.82–1.55) 0.461
Model: Potential covariates included male sex, BSA, smoking, NYHA functional class, CAD,
CABG, pulmonary hypertension, major arrhythmia, LV end-diastolic volume, LV end-systolic
volume, LV ejection fraction, LV mass, annulus diameter. Forced in covariates included post-
dilation and paravalvular aortic regurgitation (3 grades).
CI ¼ conﬁdence interval; HR ¼ hazard ratio; other abbreviations as in Tables 1 and 2.
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788as stroke will also help deﬁne indications for PD and
potentially improve outcomes.
Study limitations. Documentation of the number and he-
modynamic result of PD as well as the PVR severity and
EOA prior to PD was not captured in the procedure data-
base. Thus the effect of PD on PVR as well as valve area
could not be quantitated. Given variability among sites in
rates and reasons for PD, selection bias may be an issue that
cannot be accounted for in this analysis. In addition, in the
absence of more precise neurologic assessment and imaging,
it is impossible to know whether neurologic events are
related to PD or initial valve implantation methods. The
PARTNER I trial also did not capture pre-procedural
computed tomography data, and therefore an analysis of
valve calcium burden or location cannot be made. Finally,
although we used data from a large, randomized study with
core laboratory echocardiographic data and adjudicated
outcome data, this subanalysis was retrospective and subject
to the limitations of an observational study.Conclusions
Although PD is associated with a greater incidence of
<7-day stroke, there is no signiﬁcant association betweenTable 7. Multivariable Cox Regression Model for 1-Year Mortality or Stroke
HR (95% CI) p Value
Baseline annulus diameter 1.88 (1.30–2.72) 0.0008
Previous CABG 0.80 (0.65–0.99) 0.0417
Paravalvular aortic regurgitation
None/trace 1.16 (0.96–1.41) 0.1145
Mild 1.32 (1.06–1.65) 0.0145
Moderate/severe 2.35 (1.75–3.17) <0.0001
Post-dilation 1.12 (0.83–1.51) 0.4702
Included model covariates as in Table 6.PD and stroke beyond 7 days. Multivariable analysis shows
no signiﬁcant association between PD and mortality. PD is
associated with reduced rates of moderate or severe PPM,
with no evidence for short-term structural deterioration of
the balloon-expandable transcatheter valve. Improved sizing
algorithms to reduce the rate of PVR, as well as deﬁning
optimal candidates for successful PD, may improve overall
outcomes.
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